Resistance to any fluoroquinolone, and at least one of three injectable second-line drugs (capreomycin, kanamycin and amikacin), in addition to multidrug-resistance

Resistance to at least rifampicin and isoniacid (which is the definition of MDR-TB), in addition to any fluoroquinolone, and to at least one of the three following injectable drugs used in anti-TB treatment: capreomycin, kanamycin and amikacin

MDR TB that also is resistant to the most effective second-line therapeutic drugs used commonly to treat MDR TB: fluoroquinolones and at least one of three injectable second-line drugs used to treat TB (amikacin, kanamycin, or capreomycin)

MDR-TB plus resistance to at least one drug in both of the two most important classes of medicines in an MDR-TB regimen: fluoroquinolones and second-line injectable agents (amikacin, capreomycin or kanamycin)

MDR-TB with additional resistance to a fluoroquinolone and an injectable agent (amikacin, kanamycin or capreomycin but not streptomycin)

Severe form of MDR-TB – the strain of M. tuberculosis is multidrug resistant and has also resistance to any of the fluoroquinolones (ofloxacin, levofloxacin, moxifloxacin or gatifloxacin) and to any one of the second-line injectable agents (kanamycin, amikacin or capreomycin)

Mycobacterium tuberculosis complex isolates defined as multidrug-resistant, with additional in vitro resistance to a fluoroquinolone and one or more of the following injectable drugs: kanamycin, amikacin, capreomycin

TB with resistance to at least isoniazid and rifampicin, and resistance to a fluroquinolone and a second line injectable agent (i.e. amikacin, kanamycin or capreomycin)

Multidrug-resistant tuberculosis plus resistance to (i) any fluoroquinolone and (ii) at least one of three injectable second-line drugs (capreomycin,kanamycin and amikacin)

Subset of MDR- TB with additional resistance to a fluoroquinolone and a second-line injectable agent

Resistance to isoniazid and rifampicin, and to any fluoroquinolone, and to any of the 3 second-line injectable medicines (amikacin, capreomycin, and kanamycin)

TB caused by Mycobacterium tuberculosis (M. tuberculosis) strains that fulfil the definition of MDR/RR-TB and which are also resistant to any fluoroquinolone and at least one additional Group A drug (Group A drugs are the most potent group of drugs in the ranking of second-line medicines for the treatment of drug-resistant forms of TB using longer treatment regimens and comprise levofloxacin, moxifloxacin, bedaquiline and linezolid).

MDR TB with additional resistance to a fruoroquinalone and either kanamycin, amikacin, or capreomycin

TB disease caused by a strain of M. tuberculosis complex that is resistant to rifampicin (and may also be resistant to isoniazid), and that is also resistant to at least one fluoroquinolone (levofloxacin or moxifloxacin) and to at least one other “Group A” drug (bedaquiline or linezolid).

Is caused by M. tuberculosis strains that fulfil the definition of MDR/RR-TB and are also resistant to any FQ and at least one additional Group A drug.